The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Role of IL-1β in type 2 diabetes
Abstract
PURPOSE OF REVIEW: To understand the role of inflammation as the fundamental cause of type 2 diabetes and specifically to examine the contribution of IL-1beta. RECENT FINDINGS: Recent studies from animals, in-vitro cultures and clinical trials provide evidence that support a causative role for IL-1beta as the primary agonist in the loss of beta-cell mass in type 2 diabetes. In vitro, IL-1beta-mediated autoinflammatory process results in beta-cell death. The autoinflammation is driven by glucose, free fatty acids, leptin, and IL-1beta itself. Caspase-1 is required for IL-1beta activity and the release of free fatty acids from the adipocyte. An emerging hypothesis gains support from patients with type 2 diabetes in which an imbalance in the amount of IL-1beta agonist activity versus the specific countering by the naturally occurring IL-1 receptor antagonist (IL-1Ra) determines the outcome of islet inflammation. An important confirmation comes from clinical trials. Blockade of IL-1 receptor with anakinra, the recombinant form of IL-1Ra, or neutralizing anti-IL-1beta antibodies, provides proof-of-principle data that reducing IL-1beta activity is sufficient for correcting dysfunctional beta-cell production of insulin in type 2 diabetes, including a possibility that suppression of IL-1beta-mediated inflammation in the microenvironment of the islet allows for regeneration. SUMMARY: Monotherapy or add-on therapy targeting IL-1beta in type 2 diabetes holds promise for long-term benefits in glycemic control and possibly reducing cardiovascular events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
Self-citationThioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationAnti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationAn Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist
Aksentijevich, I., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., Laxer, R., Tedgård, U., Cowen, E. W., Pham, T.-H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807865 · Cited by 987
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Pascual, V., Allantaz, F., Arce, E., Punaro, M., & Banchereau, J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050473 · Cited by 922
β-Cell Glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes.
Robertson, R. P., Harmon, J., Tran, P. O. T., & Poitout, V. (2004) · Diabetes · doi:10.2337/diabetes.53.2007.s119 · Cited by 914
Cited by
Inflammatory responses and inflammation-associated diseases in organs
Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., Wang, X., & Zhao, L. (2018) · Oncotarget · doi:10.18632/oncotarget.23208 · Cited by 5,143
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Self-citationInflammasomes in health and disease
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012) · Nature · doi:10.1038/nature10759 · Cited by 2,230
Senescence and aging: Causes, consequences, and therapeutic avenues
McHugh, D., & Gil, J. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201708092 · Cited by 1,233
Baroja-Mazo, A., Martín-Sánchez, F., Gomez, A. I., Martínez, C. M., Amores-Iniesta, J., Compan, V., Barberà-Cremades, M., Yagüe, J., Ruiz-Ortiz, E., Antón, J., et al. (2014) · Nature Immunology · doi:10.1038/ni.2919 · Cited by 790
Oslowski, C. M., Hara, T., O'Sullivan-Murphy, B., Kanekura, K., Lu, S., Hara, M., Ishigaki, S., Zhu, L. J., Hayashi, E., Hui, S. T., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.07.005 · Cited by 675
Interleukin‐18: Biological properties and role in disease pathogenesis
Kaplanski, G. (2018) · Immunological Reviews · doi:10.1111/imr.12616 · Cited by 606
Blevins, H. M., Xu, Y., Biby, S., & Zhang, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.879021 · Cited by 587
Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders?
Parisi, L., Gini, E., Baci, D., Tremolati, M., Fanuli, M., Bassani, B., Farronato, G., Bruno, A., & Mortara, L. (2018) · Journal of Immunology Research · doi:10.1155/2018/8917804 · Cited by 508
Liu, C., Feng, X., Li, Q., Wang, Y., Li, Q., & Hua, M. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.028 · Cited by 470
The NLRP3 inflammasome in health and disease: the good, the bad and the ugly
Menu, P., & Vince, J. E. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04440.x · Cited by 389
Type 2 diabetes as a protein misfolding disease
Mukherjee, A., Morales-Scheihing, D., Butler, P. C., & Soto, C. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.005 · Cited by 342
Metabolic regulation of NLRP 3
Hughes, M. M., & O'Neill, L. A. J. (2018) · Immunological Reviews · doi:10.1111/imr.12608 · Cited by 311
Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis
Giordano, A., Murano, I., Mondini, E., Perugini, J., Smorlesi, A., Severi, I., Barazzoni, R., Scherer, P. E., & Cinti, S. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m038638 · Cited by 297
Inflammasomes on the Crossroads of Innate Immune Recognition and Metabolic Control
Próchnicki, T., & Latz, E. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.018 · Cited by 297
AGE restriction in diabetes mellitus: a paradigm shift
Vlassara, H., & Striker, G. E. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.74 · Cited by 277
β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes
Saisho, Y. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.109 · Cited by 263
Level of IL-6, TNF, and IL-1β and age-related diseases: a systematic review and meta-analysis
Tylutka, A., Walas, Ł., & Zembron-Lacny, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1330386 · Cited by 262
Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases
Liu, D., Zeng, X., Li, X., Mehta, J. L., & Wang, X. (2018) · Basic Research in Cardiology · doi:10.1007/s00395-017-0663-9 · Cited by 258
Ballak, D. B., Stienstra, R., Tack, C. J., Dinarello, C. A., & van Diepen, J. A. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.005 · Cited by 255
Self-citationMartínez-Cerón, E., Barquiel, B., Bezos, A.-M., Casitas, R., Galera, R., García-Benito, C., Hernanz, A., Alonso-Fernández, A., & Garcia-Rio, F. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-1942oc · Cited by 214
The Inflammasome in Atherosclerosis and Type 2 Diabetes
Masters, S. L., Latz, E., & O’Neill, L. A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001902 · Cited by 169
Differential Effects of Alternate-Day Fasting Versus Daily Calorie Restriction on Insulin Resistance
Gabel, K., Kroeger, C. M., Trepanowski, J. F., Hoddy, K. K., Cienfuegos, S., Kalam, F., & Varady, K. A. (2019) · Obesity · doi:10.1002/oby.22564 · Cited by 144
Caton, P. W., Kieswich, J., Yaqoob, M. M., Holness, M. J., & Sugden, M. C. (2011) · Diabetologia · doi:10.1007/s00125-011-2288-0 · Cited by 140
Wu, J., Xu, X., Li, Y., Kou, J., Huang, F., Liu, B., & Liu, K. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.09.046 · Cited by 125
IL-1β suppresses innate IL-25 and IL-33 production and maintains helminth chronicity
Zaiss, M. M., Maslowski, K. M., Mosconi, I., Guenat, N., Marsland, B. J., & Harris, N. L. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003531 · Cited by 116
Xia, M., Boini, K. M., Abais, J. M., Xu, M., Zhang, Y., & Li, P.-L. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.01.032 · Cited by 106
Prophylactic and therapeutic vaccines for obesity
Na, H.-N., Kim, H., & Nam, J.-H. (2014) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2014.3.1.37 · Cited by 16
Role of metabolic dysfunction in treatment resistance of major depressive disorder
Toups, M. S., & Trivedi, M. H. (2011) · Neuropsychiatry · doi:10.2217/npy.11.49 · Cited by 9
Metadata
- Authors
- Dinarello, C. A., Donath, M. Y., & Mandrup-Poulsen, T.
- Venue
- Current Opinion in Endocrinology, Diabetes & Obesity
- Published
- 2010-08
- Volume
- 17
- Issue
- 4
- Pages
- 314-321
- ISSN
- 1752-296X (ISSN-L)
- OpenAlex
- W1803405992
- Cited by
- 327
- References
- 46
- FWCI
- 25.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.